Clinical trial · no report yet · Phase 3
ZEST
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
- NCT04915755 ↗
- Active, not recruiting
- GlaxoSmithKline
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 11 | |
| X threads | 10 | |
| Podcasts | 6 | |
| Bluesky threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Neoplasms, Breast
- Interventions
- Niraparib; Placebo
- Arms
- Cohort1:Participants with tBRCAmut HER2-breast cancer(Independent of HR status,including HR+andTNBC) · Experimental
- Cohort 2: Participants with tBRCAwt TNBC · Experimental
- Enrollment
- 40
- Primary outcomes
- Number of Participants With Treatment Emergent Adverse Event (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
- Number of Participants With TEAEs Leading to Death
- Number of Participants With TEAEs Leading to Dose Modifications and Discontinuation of Study Treatment
- Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
- Number of Participants With Worst-Case Post-Baseline (WCPB) Hematology Results Relative to Baseline
- Number of Participants With Worst-Case Post-Baseline (WCPB) Clinical Chemistry Results Relative to Baseline
- Number of Participants With Worst-Case Post-Baseline (WCPB) Vital Signs Results Relative to Baseline
- Number of Participants With Use of Concomitant Medications
- Sponsor
- GlaxoSmithKline
- Start
- Jun 28, 2021
- Primary completion
- Jun 28, 2024
- Results posted
- Yes
- Registry record
- NCT04915755 · updated Jul 16, 2025